RxDoctor Payments Data

Valentin del Rio Santiago, MD

Interventional Cardiology · Manati, PRNPI 1790982155

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $20,500 of the $27,709 with a category attached, or 74.0%. ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) accounts for 81.2% of it on its own, with 14 other manufacturers making up the rest. Reporting peaked in 2019 at $8,900 and has fallen 91.6% since, to $747 in 2025.

$27,709in general payments, 2019–2025

Across 191 payments — averaging $145.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$22K
  • Medtronic$3K
  • Boston Scientific$1K
  • AstraZeneca$259
  • Teleflex LLC$230
  • Abbott$137
  • plus $470 from 9 others

What the payments were for

  • Speaking & faculty fees$20,50074%
  • Food & beverage$7,20926%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$27,709 in reported general payments places this provider in the 65th percentile of 39 interventional cardiology providers in Puerto Rico.

See all interventional cardiology providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$21,783
Medicare patients
132
Services billed
317

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban385$385,485
XareltoRivaroxaban92$87,460
FarxigaDapagliflozin Propanediol82$84,319
BrilintaTicagrelor98$79,764
EntrestoSacubitril/Valsartan33$35,287
Candesartan-HydrochlorothiazidCandesartan/Hydrochlorothiazid173$32,352
JardianceEmpagliflozin31$29,931
Candesartan Cilexetil128$17,923
Repatha SureclickEvolocumab26$16,913
Metoprolol Succinate886$15,606
Atorvastatin Calcium1,143$15,536
Losartan Potassium1,016$13,836
Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide410$9,947
ClopidogrelClopidogrel Bisulfate635$8,748
Carvedilol749$8,213

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Brilinta$259$164,083180 claims
Johnson & JohnsonXarelto$23$87,46092 claims
Boehringer IngelheimJardiance$43$29,93131 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 39 interventional cardiology providers in Puerto Rico.

Other interventional cardiology in Manati

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →